Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QHL
|
|||
| Former ID |
DCL000986
|
|||
| Drug Name |
Sivelestat sodium hydrate
|
|||
| Synonyms |
sivelestat sodium hydrate; Sivelestat sodium tetrahydrate; 201677-61-4; Elaspol; Sodium sivelestat; EI546 sodium; UNII-737RR8Y409; Sivelestat (sodium tetrahydrate); LY544349 sodium; Sivelestat sodium [USAN]; Sivelestat sodium (USAN); 737RR8Y409; DSSTox_CID_26727; DSSTox_RID_81857; DSSTox_GSID_46727; sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY544349 Sodium Hydrate; Elaspol (TN); CAS-201677-61-4; NCGC00167577-01; AC1L4KMF; Sivelestat sodium hydrate (JAN); Sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; Sodium ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate tetrahydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lung injury [ICD-11: NB32.3; ICD-10: J80; ICD-9: 518.5, 518.82] | Phase 4 | [1] | |
| Community-acquired pneumonia [ICD-11: CA40.Z] | Phase 2 | [2] | ||
| Company |
ONO Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H29N2NaO11S
|
|||
| Canonical SMILES |
CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)[O-].O.O.O.O.[Na+]
|
|||
| InChI |
1S/C20H22N2O7S.Na.4H2O/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24;;;;;/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24);;4*1H2/q;+1;;;;/p-1
|
|||
| InChIKey |
PLHREJBSQUSUCW-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 201677-61-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848980, 10253427, 12014432, 14934312, 46234170, 56039266, 57386948, 77060685, 92714191, 93302558, 113440824, 121278936, 126592378, 126624342, 126655598, 126670224, 134339418, 135114580, 144206123, 152040505, 152102776, 162181212, 165235284, 170465996, 184546383, 196106031, 198935522, 210275600, 210281259, 223394142, 223663430, 242585327, 252218912
|
|||
| ChEBI ID |
CHEBI:32133
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [3] |
| Serine protease unspecific (SP) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 3 | Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.